Eyedrop Pharmacology: Why Most of the Drop Is Wasted
The eyedrop looks like the simplest drug in medicine — squeeze the bottle, one drop, done. It is in fact one of the least efficient delivery routes in the whole pharmacopoeia. The eye is built to keep things out: the tear film it lands in holds barely a fifth of the drop, blinking and tear drainage flush the rest away within minutes, and only a small percentage ever crosses the cornea to reach its target. Almost everything about how ophthalmic drugs are formulated and prescribed is an attempt to cheat those losses. And the drug that does drain away doesn't vanish — it runs down into the nose and is absorbed straight into the bloodstream, which is how a drop meant for the eye can slow the whole heart.
A 71-year-old man with primary open-angle glaucoma comes to clinic worried his drops "aren't working." He is on three bottles: a prostaglandin analogue at night, a beta-blocker in the morning, and a carbonic anhydrase inhibitor twice a day. Watching him instil them tells the whole story. He tips his head back, squeezes two drops into the corner of each eye in quick succession, blinks hard several times, then dabs the overflow off his cheek. His eyelids are red and sore — chronic surface irritation from years of preservative. He puts the second bottle in the moment after the first, so it washes the first straight out. And on review his resting pulse is 52, because the timolol he has dripped into his eyes every morning for eight years has been quietly reaching his heart. Almost nothing he is doing is delivering drug the way it was meant to.
The arithmetic of a wasted drop
The problem starts before the drug even touches the eye: the drop is simply too big. The tear film — the thin layer of fluid coating the eye — holds only about 7 to 10 microlitres at any moment, and the eye can transiently hold perhaps 25 to 30 before it overflows. A drop from a standard bottle is 30 to 50 microlitres. So from the very first instant, most of the drop cannot even fit: it spills over the lid margin onto the cheek or brims out at the corner. Whatever does fit is now sitting in a puddle that the eye is desperate to clear. This mismatch — a delivery volume several times larger than the space that receives it — is the first and largest source of waste, and it is baked into the very shape of the dropper tip.
Then the eye clears the puddle fast. Tears turn over at roughly 15 to 16 percent per minute at rest, and a foreign drop provokes reflex tearing that pushes this far higher. Every blink pumps fluid through the puncta — the tiny drainage holes at the inner corner of the lids — down the nasolacrimal duct toward the nose. Within about two to five minutes the drop is essentially gone from the surface. The drug has only that brief window to cross into the eye. Against this drainage, the fraction of an applied dose that actually penetrates the cornea into the eye is famously low — often quoted as under 5 percent, sometimes far less. More than nine-tenths of the drug you dispense is designed, in effect, to be lost.
Instilling an eyedrop is like trying to fill an espresso cup from a fire hose held for one second. The cup — the tear film — is tiny; the blast is many times its volume, so most of it sprays past onto the floor. And the little that lands doesn't stay: the cup has a hole in the bottom (the puncta) draining continuously into a pipe (the nasolacrimal duct). You are not filling a reservoir; you are wetting a surface that is actively emptying itself. Every trick of ophthalmic formulation is an attempt to make the cup hold on to a few more drops for a few more seconds.
The cornea: a barrier built to keep drugs out
Even for the small fraction that gets a chance, the cornea is a deliberately awkward gate. It is layered like a sandwich with opposite solubility demands: a fatty (lipophilic) epithelium on the outside, a watery (hydrophilic) stroma in the middle, and a fatty endothelium behind. To cross, a drug must be lipophilic enough to slip through the epithelium yet hydrophilic enough to travel through the stroma — a split personality few molecules possess. A purely water-loving drug is repelled at the surface; a purely fat-loving one gets stuck in the stroma. This barrier is the same one the Foundations chapter describes when it covers the eye's defences, and it is the reason topical drugs are formulated so carefully rather than simply dissolved in water.
Formulators cheat the barrier with chemistry — most elegantly with prodrugs. One classic fix is to disguise the drug as something more fat-loving so it can cross the epithelium, then let the eye unmask it. Latanoprost, the workhorse glaucoma prostaglandin, is dispensed as an inactive lipophilic ester: it penetrates the cornea easily, and enzymes (esterases) inside the eye hydrolyse it to the active acid once it is safely across. The prodrug is the ferry; the eye's own enzymes are the dock that unloads the cargo. Dipivefrine, an older adrenaline prodrug, worked on the same principle. This is the ophthalmic version of the prodrug and lipophilicity principles taught in the Principles of Pharmacology chapter — reshaping a molecule not to change what it does, but to get it to where it must act.
- The tear film holds ~7–10 µL; a standard drop is ~30–50 µL — most of it overflows immediately.
- Tear turnover, reflex tearing and blink-driven drainage clear the drop within ~2–5 minutes.
- Corneal penetration of an applied dose is typically under ~5% — ocular bioavailability is intrinsically poor.
- The cornea is a lipid–water–lipid sandwich; a drug needs balanced solubility to cross all layers.
- Prodrugs (e.g. latanoprost) are lipophilic disguises that the eye's esterases activate after penetration.
Beating the losses: how the drops are engineered
If the drug leaves too quickly, make it stay longer. Viscosity agents — cellulose derivatives, polyvinyl alcohol and similar polymers — thicken the drop so it resists drainage and clings to the surface, stretching the contact time. Go further and you get gels, which are near-solid on contact, and ointments, greasy vehicles that sit in the fornix and release drug slowly for hours — which is exactly why ointments are favoured at bedtime, when blurred vision doesn't matter and long contact does. Suspensions add another angle: fine particles of a poorly soluble drug (many topical steroids are suspensions) form a reservoir that dissolves gradually — which is also why a suspension bottle must be shaken before use, or the dose is wrong.
Two practical rules fall straight out of the arithmetic. First: one drop is enough. The eye already can't hold one full drop, so a second drop the instant after the first simply washes the first away and doubles the cost and the toxicity for no extra effect. Second: wait about five minutes between two different drops. Instil them back-to-back and the second drop floods out the first before it has absorbed — you are paying for two medicines and delivering a fraction of one. The order of the day-to-day glaucoma routine matters, and this single instruction can turn a "failing" regimen into a working one without changing a single drug.
The preservative problem: BAK
A multi-dose bottle must stay sterile between drops — and the classic guardian is a double-edged sword. Benzalkonium chloride (BAK) is the most widely used preservative in eyedrops, a detergent that kills any bacteria that get into the bottle. It has a curious bonus: by disrupting the lipid of the corneal epithelium, BAK actually loosens the barrier and can enhance the penetration of the drug it accompanies. But that same detergent action is toxic to the ocular surface. With occasional use it is harmless; with chronic daily use it strips the tear film's lipid, damages the surface epithelium and the goblet cells, and produces a red, gritty, dry, inflamed eye. The patient who suffers most is precisely the one exposed most: the glaucoma patient on several BAK-containing bottles, several times a day, for the rest of their life. Over years, that cumulative toxicity can inflame the surface enough to threaten the very drops they depend on — and even compromise the outcome of future glaucoma surgery.
The answer is preservative-free formulations — single-use vials, or special multi-dose bottles with a one-way valve and filter that keep the contents sterile without a chemical biocide. They cost more and are fiddlier, but for a patient facing decades of lifelong drops, sparing the ocular surface is worth it. This surface toxicity is the recurring theme of the Glaucoma chapters, where lifelong multi-drop regimens make BAK exposure a central management problem rather than a footnote.
The escape route: how an eyedrop reaches the heart
The drug that drains away doesn't disappear — it takes a shortcut into the bloodstream. Follow the overflow. Most of the dose leaves through the puncta, down the nasolacrimal duct, and onto the highly vascular nasal mucosa. There it is absorbed directly into the systemic circulation — and, crucially, it bypasses the liver. A swallowed drug is first carried to the liver and partly destroyed before it reaches the body (first-pass metabolism); a drug absorbed across the nasal mucosa skips that filter entirely, exactly as the Principles of Pharmacology chapter explains for sublingual and nasal routes. So an eyedrop is, in effect, a small, unregulated systemic dose delivered by a route that avoids first-pass breakdown. "It's only an eyedrop" is one of the most misleading phrases in the clinic.
Timolol, the topical beta-blocker used for glaucoma, is the textbook case: absorbed through the nose it can cause systemic beta-blockade — bradycardia, hypotension, and bronchospasm — which is why it is dangerous in asthma, COPD and heart block, and why it can slow the pulse of a patient who thinks he is only treating his eyes. Topical alpha-agonists like brimonidine can cause drowsiness, dry mouth and, in infants, dangerous CNS depression and apnoea. Anticholinergic mydriatics such as atropine can produce systemic anticholinergic effects — flushing, tachycardia, confusion — especially in small children. Phenylephrine drops can raise blood pressure. In every case the eye is merely the entry point; the systemic effect is the drainage escaping into the body.
One move that fixes both problems: punctal occlusion
There is a single, free, drug-free manoeuvre that improves the ocular effect and the systemic safety at the same time. After instilling the drop, gently close the eyes and press a fingertip on the inner corner — over the punctum — for one to two minutes. This is punctal occlusion (with eyelid closure). By blocking the drainage hole, it does two things at once: it keeps the drug on the eye longer, raising the amount that penetrates, and it stops the drug running down the nose, cutting the systemic absorption. Better ocular effect and fewer systemic side effects from the same drop — a rare win-win in pharmacology, and the simplest way to make timolol safer in a patient you'd rather not put on a systemic beta-blocker at all.
None of this matters if the bottle stays in the cupboard. The final loss is behavioural. Chronic ophthalmic regimens — glaucoma above all — depend on a patient reliably instilling irritating drops, often several bottles on different schedules, every single day for years, to treat a disease that causes no symptoms until sight is already lost. Adherence is poor, and the drop that is never taken has zero bioavailability. Simplifying the regimen (once-daily prostaglandin analogues, fixed-combination bottles that merge two drugs into one), removing the surface irritation (preservative-free formulations), and teaching correct technique (one drop, eyes closed, punctal pressure, five minutes apart) are not niceties — they are how the pharmacology actually reaches the eye in real life.
- Viscosity agents, gels, ointments and suspensions all work by prolonging contact time on the eye.
- BAK preserves the bottle and boosts penetration but is toxic to the ocular surface with chronic use.
- Preservative-free formulations spare the surface in lifelong, multi-drop glaucoma regimens.
- Nasolacrimal drainage → nasal absorption bypasses first-pass metabolism → systemic drug effect.
- Punctal occlusion + eyelid closure raises ocular effect AND cuts systemic absorption at once.
- One drop is enough; space different drops ~5 minutes apart; adherence is the final bioavailability barrier.
- Telling patients to put in two drops "to be sure" — the eye can't hold a second drop, so it just washes out the first and doubles the toxicity.
- Instilling two different drops back-to-back, so the second flushes the first away before it has absorbed — always space them ~5 minutes.
- Dismissing timolol as "just an eyedrop" in an asthmatic or bradycardic patient — nasal absorption delivers real systemic beta-blockade.
A 68-year-old with well-controlled asthma is started on topical timolol for glaucoma and returns a fortnight later with wheeze and a resting pulse of 48. Which single instruction would most reduce the systemic drug reaching her lungs and heart from each dose?
- The eyedrop is a study in poor bioavailability: the tear film holds ~7–10 µL but a drop is ~30–50 µL, and drainage clears it in minutes, so typically under ~5% penetrates the cornea.
- Formulation fights the losses — viscosity agents, gels, ointments and suspensions prolong contact; prodrugs like latanoprost cross the lipid–water cornea and are activated inside the eye.
- BAK preservative enhances penetration but is toxic to the ocular surface long-term; preservative-free formulations matter most for lifelong glaucoma drops.
- Drug draining down the nose is absorbed systemically, bypassing first-pass metabolism (timolol → beta-blockade); one drop is enough, space drops ~5 min, and punctal occlusion improves both effect and safety.
- Bartlett JD, Jaanus SD. Clinical Ocular Pharmacology — Ocular drug delivery and pharmacokinetics.
- Kanski's Clinical Ophthalmology: A Systematic Approach — Principles of medical therapy and glaucoma medications.
- American Academy of Ophthalmology, Basic and Clinical Science Course (BCSC) — Fundamentals and Principles of Ophthalmology; Glaucoma.
- Rang & Dale's Pharmacology — Routes of administration and ocular drug delivery.
- Katzung's Basic & Clinical Pharmacology — Drugs used in ocular disorders.
- Royal College of Ophthalmologists / NICE guidance on glaucoma (NG81) — topical therapy, preservative toxicity and adherence.
